Search

Search Constraints

You searched for: Author/Creator Carlton, Kevin

Search Results

1. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Issue 10 (October 2021)

2. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. (June 2022)

3. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. Issue 8 (August 2022)

4. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. (4th February 2022)

5. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Issue 10174 (2nd March 2019)

6. Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development. (29th August 2022)

7. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. Issue 11 (26th November 2020)

8. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. Issue 1 (1st January 2021)

9. Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency. Issue 1 (31st December 2023)

10. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. Issue 4 (April 2023)